Primary immune-mediated haemolytic anaemia: a retrospective long-term study in 61 dogs.

Abstract

OBJECTIVES: The objective of this study is to describe the course of disease of dogs with primary immune-mediated haemolytic anaemia (pIMHA) with an observation period longer than 90&#x2009;days in regard to clinical signs, laboratory results and treatment response. MATERIAL AND METHODS: Clinical records between January 2003 and December 2011 were reviewed. Diagnosis of pIMHA was based on the presence of haemolytic anaemia with a packed cell volume of <0.35 L/L, a positive Coombs' test and/or erythrocyte agglutination, spherocytosis and exclusion of an underlying disease. Included were dogs which could be monitored for more than 90&#x2009;days after initial presentation. RESULTS: Sixty-one dogs with pIMHA were included. The initial packed cell volume ranged from 0.08 to 0.30 L/L (median 0.16). Immunosuppressive treatment included prednisolone in all the cases; 32 dogs successively received cyclosporine (28), cyclophosphamide (5), leflunomide (2) or human intravenous immunoglobulins (2) in addition. In 33/61 dogs, the drugs were discontinued 67-3372&#x2009;days (median 334) after beginning of therapy; in 28 dogs, the drug dosage was reduced, but not discontinued until the end of the study. Three dogs developed immune-mediated thrombocytopenia (days 132, 156 and 680). The observation period ranged from 96 to 4147&#x2009;days (median 628). A total of 22.9% (14/61) of the dogs developed a relapse after 94-3972&#x2009;days (median 517). Five dogs were euthanased due to a relapse after 96-1188&#x2009;days (median 628). CLINICAL SIGNIFICANCE: Long-term prognosis in dogs with pIMHA is favourable. However, a relapse can occur after many years. Relapse was the most common cause of death in dogs with pIMHA that survive more than 90&#x2009;days.